Xiang H. F. Zhang, PhD
William T. Butler Professor
Baylor College of Medicine
Dr. Xiang Zhang obtained his Ph.D. degree from Columbia University in 2006, and did his postdoctoral training at Memorial Sloan Kettering Cancer Center from 2006 to 2011. He was then recruited to the Breast Center of Baylor College of Medicine as a McNair Scholar, and is now the William T. Butler Endowed Professor. His lab focuses on metastatic breast cancer, and has made seminal contributions in two areas: 1) bone metastasis and 2) tumor immunology and immunotherapies. In the former, he discovered the osteogenic niche that promotes early-stage bone colonization (Wang et al., Cancer Cell; 2015, Wang et al., Cancer Cell, 2018; Zhang et al., Cell, 2021; and Bado et al., Developmental Cell), and invented a series of pre-clinical models and technologies to accelerate anti-metastasis drug discovery (Wang et al., Nature Communications 2017). In the latter, he uncovered the link between oncogenic mTOR signaling and recruitment of myeloid-derived suppressor cells (Welte, et al., Nature Cell Biology, 2016), and a mutual regulatory loop between tumour vasculature and immunostimulatory reprogramming (Tian et al., Nature, 2017). More recently, he demonstrated how different immunosubtypes of tumor microenvironment may affect responses to checkpoint blockade therapies (Kim et al., Nature Cell Biology, 2019), and exhibit different responses to NK cell-mediated cytotoxicity (Lo et al., Nature Cancer, 2020). These discoveries have made significant impacts in our understanding of tumor-microenvironment interactions and the consequent effects on therapies.
Dr. Zhang is the first or corresponding author of over 30 papers published in journals including Cell, Nature, Cancer Cell, Nature Cell Biology, Developmental Cell, Nature Cancer, Nature Communications, Genes and Development, PNAS, Genome Research and MCB. He also co-authored another 50 papers published in Cell, Nature, Cancer Cell, Nature Medicine and etc. His awards include “Thesis with Distinction” by Columbia University (2006), the McNair Scholarship by Baylor College of Medicine (2011), Pathway to Independence Award by NCI (2010-2014), DoD BCRP Era of Hope Scholarship (2016), Excellent in Research Award of MCB, BCM (2016), Theresa Foundation Leadership Award (2016), and Susan G. Komen Career Catalyst Award (2014-2017), Michael E. DeBakey Award for Excellence in Research, BCM (2018), Sue Eccles Young Investigator Award by the Metastasis Research Society (2018), and Laura Zisken Award of Translational Breast Cancer Research (2020). He is a co-director of the annual Metastatic Breast Cancer Conference. He is an ad hoc reviewer of Nature, Science, Cell, Nature Medicine, Nature Cancer, Nature Cell Biology, Nature Communications, Cancer Cell, Cell Stem Cell, Cell Reports, PNAS, JEM, Cancer Research, RNA, Nucleic Acid Research, BMC Bioinformatics, Breast Cancer Cancer Research and Treatment and Breast Cancer Research, and is an active member of American Association of Cancer Research (since 2012), Metastasis Research Society (since 2015), and American Association of Immunology (since 2016).